We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.
1 / 3 
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.
Learn More
We are led by a team of veteran biopharma executives who bring exceptional track records of developing and commercializing transformative therapies.
Learn MoreGuided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.
Participants Dosed with Izokibep
Dedicated Professionals
Growth financing committed
Clinical-stage programs
We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.
ACELYRIN, backed with more than $550 million in venture capital, adds to drug pipeline
Any biotech that can rake in half a billion dollars from investors in 12 months is clearly doing something right.
Unique IL-17A inhibitor demonstrated notable dose-dependent improvements in sleep, pain and function in patients with psoriatic arthritis.